Study Title
Health Plan Disenrollment and Mortality After Starting Medications for Opioid Use Disorder
Why This Study Matters
Opioid use disorder (OUD) is a serious, chronic medical condition that can be treated with medications such as buprenorphine and naltrexone. These treatments reduce cravings, help prevent relapse, and lower the risk of overdose. But treatment does not happen in a vacuum. People also need steady access to health care, prescriptions, follow-up visits, and behavioral support.
When someone loses health insurance coverage or is removed from a health plan, that disruption may interrupt care at exactly the wrong time. For patients receiving medication for OUD, a gap in coverage can mean missed prescriptions, delayed appointments, reduced access to counseling, and less contact with clinicians. Because overdose risk is already high in this population, even a short break in care may have serious consequences.
This study examined whether disenrollment from a health plan after starting medication for OUD was associated with a higher risk of death, including overdose death.
What the Researchers Studied
This was a large cohort study of 20,011 patients aged 16 years or older who began treatment with either buprenorphine or naltrexone for OUD between January 1, 2012, and December 31, 2021. The patients were enrolled in 3 integrated health insurance and care delivery systems in 2 US states. These systems combined insurance coverage and medical care, allowing researchers to track enrollment, treatment, and outcomes over time.
Patients were followed for up to 2 years, through December 31, 2022. The investigators then linked the records with the National Death Index to determine deaths from any cause and deaths related to overdose, including drug-related and alcohol-related overdose.
The study also adjusted for many patient factors, including demographic and clinical characteristics, so the results would better reflect the relationship between disenrollment and mortality rather than differences in the types of patients who lost coverage.
Who Was Included
Among the 20,011 patients:
– The average age was 38.7 years.
– 61.5% were male.
– 34.7% experienced health plan disenrollment at some point during follow-up.
– 2.9% died during the study period.
These numbers show that disenrollment was common and that mortality remained a clinically important outcome in this population.
Main Findings
The overall crude mortality rate was 15.3 deaths per 1,000 person-years for all-cause mortality and 6.2 deaths per 1,000 person-years for overdose mortality.
Patients who ever experienced disenrollment had higher death rates than those who remained enrolled:
– All-cause mortality: 17.6 vs 14.7 per 1,000 person-years
– Overdose mortality: 8.9 vs 5.4 per 1,000 person-years
After statistical adjustment, ever experiencing disenrollment was associated with:
– 51% higher hazard of death from any cause (hazard ratio [HR], 1.51)
– 56% higher hazard of overdose death (HR, 1.56)
The study also compared different care states. Compared with patients who remained enrolled and continued receiving medication for OUD, two groups had much higher mortality:
– Patients who were disenrolled: HR 4.34
– Patients who stayed enrolled but were not receiving medication for OUD: HR 4.19
This is an important finding because it suggests that ongoing treatment and stable coverage both matter. The highest risk appeared among people who lost coverage or were not maintained on medication.
What the Results Mean
The findings support a simple but critical idea: continuity of care saves lives.
For people with OUD, insurance coverage is not just an administrative issue. It is often the pathway to medication access, primary care, mental health treatment, and overdose prevention services. When coverage ends, patients may face barriers such as:
– Delays in refilling medications
– Loss of a trusted clinician or treatment program
– Higher out-of-pocket costs
– Missed opportunities for counseling and follow-up
– Reduced access to naloxone and other harm-reduction tools
These disruptions can increase the chance of relapse, overdose, or death. The results are also consistent with what is known about OUD treatment: medications like buprenorphine and naltrexone are most effective when people can stay in care consistently.
About the Medications
Buprenorphine is a partial opioid agonist that helps reduce withdrawal symptoms and cravings while lowering overdose risk compared with full opioid agonists. It is widely used because it can be prescribed in outpatient settings and supports longer-term treatment.
Naltrexone is an opioid antagonist that blocks the effects of opioids. It is usually started after a patient has fully stopped using opioids, because taking it too early can trigger withdrawal. Extended-release injectable naltrexone can help some patients maintain abstinence, but it also requires stable follow-up and access to care.
Both medications can be highly beneficial, but both depend on continuity. If a patient loses insurance or cannot access refills, treatment may stop abruptly.
Why Disenrollment May Increase Risk
Health plan disenrollment can affect mortality in several ways. First, it can interrupt medication access, which may increase cravings and relapse risk. Second, patients may lose contact with clinicians who monitor progress, manage side effects, and adjust treatment when needed. Third, disenrollment may reflect broader instability in a patient’s life, such as job loss, housing insecurity, or administrative barriers, all of which can also worsen health outcomes.
In other words, disenrollment may be both a direct cause of treatment interruption and a marker of vulnerability. Either way, it identifies a period when patients may be especially at risk.
Clinical and Policy Implications
This study has practical implications for clinicians, insurers, and policymakers.
For clinicians, it reinforces the importance of planning ahead when a patient may lose coverage. That may include early refill coordination, warm handoffs to new providers, help with patient assistance programs, and prescribing naloxone.
For health systems and insurers, the findings argue for smoother transitions between plans, faster re-enrollment processes, and fewer interruptions in medication coverage. Continuity of buprenorphine or naltrexone should be treated as a safety issue, not merely a billing issue.
For policymakers, the study highlights the need for insurance policies that support uninterrupted treatment for OUD, especially during employment changes, plan transitions, or eligibility redeterminations. Reducing coverage gaps could be a meaningful strategy to prevent overdose deaths.
Strengths of the Study
This study had several strengths. It included a large number of patients, used real-world data from integrated care systems, and examined both all-cause and overdose mortality. The researchers also adjusted for a range of patient characteristics, which strengthens the validity of the findings.
Another major strength was the use of death registry data, which is more reliable than relying only on medical records for mortality outcomes.
Limitations to Keep in Mind
As with all observational studies, this research cannot prove that disenrollment directly caused the deaths. People who lose insurance may differ in important ways from those who remain enrolled, including differences in social stress, disease severity, or substance use patterns that are difficult to measure completely.
The study also focused on patients in integrated health systems in two US states, so the results may not apply equally to all insurance arrangements or care settings. In addition, the analysis did not capture every possible detail about treatment adherence, illegal drug supply exposure, or social factors such as housing instability.
Even with these limitations, the findings are strong enough to raise concern and support action.
Bottom Line
Among patients who started medication for opioid use disorder, losing health plan coverage was associated with a significantly higher risk of death, including overdose death. Patients who stayed enrolled and continued treatment had the lowest risk.
The message is clear: treating opioid use disorder requires more than prescribing medication. Stable insurance coverage, uninterrupted access to care, and careful transition support are all essential parts of saving lives.